b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">32212266</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1097-0215</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>147</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Sep</Month>\n                        <Day>15</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>International journal of cancer</Title>\n                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>PTPN11 mutations in canine and human disseminated histiocytic sarcoma.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1657-1665</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.32991</ELocationID>\n            <Abstract>\n                <AbstractText>In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge. Sharing high clinical and histopathological similarities with human HS, the canine HS is conversely frequent in specific breeds and thus constitutes a unique spontaneous model for human HS to decipher the genetic bases and to explore therapeutic options. We identified sequence alterations in the MAPK pathway in at least 63.9% (71/111) of HS cases with mutually exclusive BRAF (0.9%; 1/111), KRAS (7.2%; 8/111) and PTPN11 (56.75%; 63/111) mutations concentrated at hotspots common to human cancers. Recurrent PTPN11 mutations are associated to visceral disseminated HS subtype in dogs, the most aggressive clinical presentation. We then identified PTPN11 mutations in 3/19 (15.7%) human HS patients. Thus, we propose PTPN11 mutations as key events for a specific subset of human and canine HS: the visceral disseminated form. Finally, by testing drugs targeting the MAPK pathway in eight canine HS cell lines, we identified a better anti-proliferation activity of MEK inhibitors than PTPN11 inhibitors in canine HS neoplastic cells. In combination, these results illustrate the relevance of naturally affected dogs in deciphering genetic mechanisms and selecting efficient targeted therapies for such rare and aggressive cancers in humans.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2020 UICC.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>H\xc3\xa9dan</LastName>\n                    <ForeName>Benoit</ForeName>\n                    <Initials>B</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0002-2418-1868</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rault</LastName>\n                    <ForeName>M\xc3\xa9lanie</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Abadie</LastName>\n                    <ForeName>J\xc3\xa9r\xc3\xb4me</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Biology, Pathology and Food Sciences, Oniris, Laboniris, Nantes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ulv\xc3\xa9</LastName>\n                    <ForeName>Ronan</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Botherel</LastName>\n                    <ForeName>Nadine</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Devauchelle</LastName>\n                    <ForeName>Patrick</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Micen Vet - Cr\xc3\xa9teil, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Copie-Bergman</LastName>\n                    <ForeName>Christiane</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Assistance Publique-H\xc3\xb4pitaux de Paris, D\xc3\xa9partement de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Cr\xc3\xa9teil, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>INSERM U955, \xc3\x89quipe 9, Facult\xc3\xa9 de M\xc3\xa9decine, Universit\xc3\xa9 Paris Est Cr\xc3\xa9teil, Cr\xc3\xa9teil, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cadieu</LastName>\n                    <ForeName>Edouard</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Parrens</LastName>\n                    <ForeName>Marie</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, CHU de Bordeaux, H\xc3\xb4pital du Haut L\xc3\xa9v\xc3\xaaque, INSERM U1035, Universit\xc3\xa9 de Bordeaux, Bordeaux, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Alten</LastName>\n                    <ForeName>Julia</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatric Oncology/Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zalcman</LastName>\n                    <ForeName>Emmanuelle L</ForeName>\n                    <Initials>EL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neuropathology, GHU Paris Psychiatrie Neurosciences, Sainte-Anne Hospital, Paris, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cario</LastName>\n                    <ForeName>Gunnar</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pediatric Oncology/Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Damaj</LastName>\n                    <ForeName>Gandhi</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Haemalology Institute, CHU de Caen and Centre Fran\xc3\xa7ois Baclesse, Caen, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mokhtari</LastName>\n                    <ForeName>Karima</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sorbonne University, Inserm, CNRS, Institut du Cerveau et de la Moelle \xc3\xa9pini\xc3\xa8re, ICM, AP-HP, H\xc3\xb4pitaux Universitaires La Piti\xc3\xa9 Salp\xc3\xaatri\xc3\xa8re - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Le Loarer</LastName>\n                    <ForeName>Francois</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Centre L\xc3\xa9on B\xc3\xa9rard, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Coulomb-Lhermine</LastName>\n                    <ForeName>Aurore</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, Trousseau Hospital, Paris, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Derrien</LastName>\n                    <ForeName>Thomas</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hitte</LastName>\n                    <ForeName>Christophe</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bachelot</LastName>\n                    <ForeName>Laura</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Breen</LastName>\n                    <ForeName>Matthew</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, CVM Research Building, Raleigh, NC, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gilot</LastName>\n                    <ForeName>David</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Blay</LastName>\n                    <ForeName>Jean Y</ForeName>\n                    <Initials>JY</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0001-7190-120X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Centre L\xc3\xa9on B\xc3\xa9rard, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Donadieu</LastName>\n                    <ForeName>Jean</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Haematology, APHP, Trousseau Hospital, Paris, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Andr\xc3\xa9</LastName>\n                    <ForeName>Catherine</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, CNRS-University of Rennes 1, UMR6290, Institute of Genetics and Development of Rennes, SFR Biosit, Rennes, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>ANR-11-INBS-0003</GrantID>\n                    <Agency>Agence Nationale de la Recherche</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>1557</GrantID>\n                    <Agency>American Kennel Club Canine Health Foundation</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>2446</GrantID>\n                    <Agency>American Kennel Club Canine Health Foundation</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>2667</GrantID>\n                    <Agency>American Kennel Club Canine Health Foundation</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>2012-103</GrantID>\n                    <Agency>INCa PLBio</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>04</Month>\n                <Day>08</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Int J Cancer</MedlineTA>\n            <NlmUniqueID>0042124</NlmUniqueID>\n            <ISSNLinking>0020-7136</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">PTPN11</Keyword>\n            <Keyword MajorTopicYN="N">dog</Keyword>\n            <Keyword MajorTopicYN="N">histiocytic sarcoma</Keyword>\n            <Keyword MajorTopicYN="N">spontaneous model</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32212266</ArticleId>\n            <ArticleId IdType="doi">10.1002/ijc.32991</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>References</Title>\n            <Reference>\n                <Citation>Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127:2672-81.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014;65:261-72.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kordes M, Roring M, Heining C, et al. Cooperation of BRAF and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 2015;30:937-46.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liu Q, Tomaszewicz K, Hutchinson L, et al. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. Virchows Arch Int J Pathol 2016;469:233-41.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Shanmugam V, Griffin GK, Jacobsen ED, et al. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol 2019;32:830-43.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Michonneau D, Kaltenbach S, Derrieux C, et al. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 2014;32:e117-21.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154-65.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Idbaih A, Mokhtari K, Emile J-F, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 2014;83:1478-80.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Abadie J, Hedan B, Cadieu E, et al. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. J Hered 2009;100(Suppl 1):S19-27.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hedan B, Thomas R, Motsinger-Reif A, et al. Molecular cytogenetic characterization of canine histiocytic sarcoma: a spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer 2011;11:201.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Shearin AL, Hedan B, Cadieu E, et al. The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer. Cancer Epidemiol Biomark Prev 2012;21:1019-27.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ulve R, Rault M, Bahin M, et al. Discovery of human-similar gene fusions in canine cancers. Cancer Res 2017;77:5721-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Alten J, Klapper W, Leuschner I, et al. Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2015;62:1656-60.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bamford S, Dawson E, Forbes S, et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004;91:355-8.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Takada M, Smyth LA, Thaiwong T, et al. Activating mutations in PTPN11 and KRAS in canine histiocytic sarcomas. Genesis 2019;10:505.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Rehman AU, Rahman MU, Khan MT, et al. The landscape of protein tyrosine phosphatase (Shp2) and cancer. Curr Pharm Des 2018;24:3767-77.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Egan C, Nicolae A, Lack J, et al. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica 2019;105:951-960.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Prahallad A, Heynen GJJE, Germano G, et al. PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Rep 2015;12:1978-85.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Grosskopf S, Eckert C, Arkona C, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. ChemMedChem 2015;10:815-26.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Voruz S, Cairoli A, Naveiras O, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica 2018;103:e39-41.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Batra S, Martin SC, Nassiri M, et al. Histiocytic sarcoma associated with coombs negative acute hemolytic anemia: a rare presentation. Case Rep Oncol Med 2016;2016:3179147.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhang Q, Shibani A, Sadikovic B, et al. An aggressive multifocal primary CNS histiocytosis with PTPN11 (Shp2) mutation. Neuropathol Appl Neurobiol 2018;44:240-3.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Goyal G, Lau D, Nagle AM, et al. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood 2019;133:1607-10.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Holderfield M, Deuker MM, McCormick F, et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gounder MM, Solit DB, Tap WD. Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med 2018;378:1945-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Takada M, Hix JML, Corner S, et al. Targeting MEK in a translational model of histiocytic sarcoma. Mol Cancer Ther 2018;17:2439-50.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'